Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18375211 | 1.00 | KMT2A (0.55) | KMT2AEPHX2CASP3CTRB1MDM4 | |
| SCHEMBL20369405 | 1.00 | KMT2A (0.55) | KMT2AEPHX2CASP3CTRB1MDM4 | |
| SCHEMBL24305580 | 0.89 | KMT2A (0.50) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL29426426 | 0.89 | KMT2A (0.50) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL19080574 | 0.83 | KMT2A (0.59) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL1769671 | 0.83 | MDM4 (0.55) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL1486272 | 0.83 | MDM4 (0.55) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL29367928 | 0.83 | MDM4 (0.55) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL29367649 | 0.83 | MDM4 (0.55) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL30977663 | 0.83 | MDM4 (0.55) | KMT2AEPHX2CASP3MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11484525-B2 | Mu opioid receptor modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-11-01 | — | — | US | disclosed |
| EP-3319444-B1 | MU OPIOID RECEPTOR MODULATORS | UNIV CALIFORNIA (US) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11484525-B2 | Mu opioid receptor modulators | OPRM1, OPRK1, OPRD1 | KMT2A 3011/4885EPHX2 1451/4885CASP3 4802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.